Aura Biosciences releases corporate deck outlining bel-sar strategy in ocular oncology

• Aura Biosciences highlighted bel-sar as a potential vision-preserving frontline therapy for early choroidal melanoma, a segment estimated at about 11,000 cases yearly.
• Phase 3 CoMpass registration trial is fully enrolled with 108 participants, backed by an FDA Special Protocol Assessment; primary endpoint is time to tumor progression.
• Topline data from the 15-month primary efficacy analysis are projected for 2H 2027; trial includes a sham-control arm with global sites.
• Phase 2 data showed 80% tumor control at 12 months in phase 3-eligible patients on a 3-cycle regimen; 9 of 10 preserved visual acuity.
• Cash runway under the current operating plan is expected into 1H 2029; bel-sar development also targets choroidal metastases and ocular surface cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.